Type I Gaucher Disease Clinical Trial
Official title:
An Open-Label, Dose Escalation With 2 Dose Levels, Proof-of-Concept Clinical Trial of Ambroxol for the Treatment of Type I Gaucher Disease
| Verified date | February 2012 |
| Source | Exsar Corporation |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Food and Drug Administration |
| Study type | Interventional |
Ambroxol is expected to improve the signs and symptoms of patients with Type I Gaucher Disease.
| Status | Suspended |
| Enrollment | 20 |
| Est. completion date | August 2015 |
| Est. primary completion date | December 2014 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 16 Years and older |
| Eligibility |
Inclusion Criteria: - Biochemically and genetically confirmed diagnosis of Gaucher disease caused by ß-glucocerebrosidase deficiency resulting from mutations in the GBA genes, which have been shown to respond to Ambroxol according to in vitro screening assay. - Must be 16 years of age or older at the time of study initiation. - With an intact, enlarged spleen. - A hemoglobin level of at least 10 g/L. - Able to understand and cooperate with the requirements of the study protocol. - Mentally competent, have ability to understand and willingness to sign the informed consent form. - Able to travel to a participating study site. - Women of child-bearing potential must use accepted contraceptive methods, and must have a negative serum or urine pregnancy test within one week prior to treatment initiation. An additional pregnancy test is to be performed, and results obtained, prior to administration of the first dose of Ambroxol. - Fertile men must practice effective contraceptive methods during the study period, unless documentation of infertility exists. - Body weight >40 kg (88 lbs). Exclusion Criteria: - Receipt of any form of glucocerebrosidase <<4 weeks prior study initiation. - Total splenectomy. - Serious medical illness, significant cardiac disease, chronic bronchitis, emphysema, and cystic fibrosis, as well as disorders causing ventilation perfusion mismatch. - Substance abuse. - Any complex disease that may confound treatment assessment. - Pregnant women, or women of child-bearing potential not using reliable means of contraception. - Lactating females because of the potential for adverse reactions in nursing infants. - Fertile men unwilling to practice contraceptive methods during the study period. - Unwilling or unable to follow protocol requirements. - Known hypersensitivity reactions, intolerance or adverse reactions to Ambroxol or to the inactive ingredients. - Evidence of systemic infection, or serious infection within the past month. - Known to have HIV infection. - Known to have hepatitis B or hepatitis C. - Patients with a history of convulsive disorders. - Patients receiving any other investigational treatment for any indication within the past 4 weeks prior to initiation of Ambroxol treatment. - A history of cancer of any type. - Patients who have received immunotherapy of any type within the past 4 weeks prior to study initiation. - Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients. |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United States | ExSAR Corporation | Monmouth Junction | New Jersey |
| Lead Sponsor | Collaborator |
|---|---|
| Exsar Corporation |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Safety assessment based on potential changes in physical exam, vital signs, ECG, adverse event query, and clinical lab results, when compared to baseline values. | Safety will be based on physical exam, vital signs, ECG, adverse event query, and clinical pathology (includes chemistry, hematology and coagulation), asessed at baseline and approximately biweekly during the study. | Safety will be assessed at baseline and biweekly for 2 months. | Yes |
| Secondary | efficacy based on biomarker (glucocerebrosidase activities), lab results, as well as hepatic and splenic volumes from imaging scans. | Efficacy is based on biomarker (glucocerebrosidase activities), phenotypes according to specific lab results (acid phosphatase, angiotensin-converting enzyme, serum bilirubin, hemoglobin, platelet counts, peripheral blood leukocyte counts, serum iron, clotting time, etc.), as well as hepatic and splenic volumes. | Biomarker, lab results (phenotype), as well as hepatic and spenic volumes will be assessed at baseline and after 2 months of treatment, and lab results (phenotypes) will also be assessed biweekly during the 2-month treatment period. | No |